69.65MMarket Cap5.56P/E (TTM)
0.895High0.860Low494.96KVolume0.890Open0.867Pre Close435.81KTurnover0.74%Turnover RatioLossP/E (Static)78.26MShares5.85052wk High-2.97P/B59.17MFloat Cap0.83352wk Low--Dividend TTM66.49MShs Float35.000Historical High--Div YieldTTM4.04%Amplitude0.833Historical Low0.880Avg Price1Lot Size
CytomX Stock Forum
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics, Inc. (Nasdaq: CTMX) unveiled positive initial data from its ongoing CX-904 Phase 1a dose escalation clinical study. This pivotal study is centered around CX-904, an investigational PROBODY® T-cell engager that is both masked and conditionally activated, designed to target t...
No comment yet